Departments of Medicine (Division of Gastroenterology and Hepatology) and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Departments of Medicine (Division of Gastroenterology and Hepatology) and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA; Veterans Administration Medical Center, Palo Alto, California.
Curr Opin Virol. 2017 Jun;24:55-59. doi: 10.1016/j.coviro.2017.04.004. Epub 2017 May 2.
Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis and is associated with a higher risk of cirrhosis, liver decompensation and liver cancer. Interferon alpha is the only agent that has demonstrated efficacy to date, although response rates are low and it is associated with significant side effects. A better understanding of the relevant molecular virology has resulted in the identification of new candidate targets. Future therapeutic options are rapidly evolving as several new agents have entered clinical development, including the entry inhibitor myrcludex-B, the nucleic acid polymer REP2139-Ca inhibiting HBV surface antigen secretion, the farnesyltransferase inhibitor lonafarnib that targets virus assembly, and a better tolerated interferon-interferon lambda.
丁型肝炎病毒（HDV）可导致最严重的人类病毒性肝炎，并且与肝硬化、肝功能失代偿和肝癌的风险增加相关。迄今为止，干扰素-α是唯一被证实有效的药物，尽管应答率较低，且与显著的副作用相关。对相关分子病毒学的更好理解导致了新候选靶点的鉴定。随着几种新药物进入临床开发，未来的治疗选择正在迅速发展，包括进入抑制剂 myrcludex-B、抑制 HBV 表面抗原分泌的核酸聚合物 REP2139-Ca、针对病毒组装的法尼酯转移酶抑制剂 lonafarnib 以及耐受性更好的干扰素-干扰素 lambda。
